Adial Pharmaceuticals Inc (ADIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has a cash flow conversion efficiency ratio of -0.434x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.61 Million) by net assets ($3.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADIL net asset quality index to measure how much of total assets are equity-financed.
Adial Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Adial Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Adial Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adcore Inc
TO:ADCO
|
0.406x |
|
Trinity Freehold & Leasehold PRP Fund
BK:TNPF
|
0.002x |
|
Mecanica Sa Ce
RO:MECF
|
N/A |
|
JPMorgan Global Emerging Markets Investment Trust PLC
LSE:JEMI
|
0.010x |
|
LCK Global Kedaton
JK:LCKM
|
0.002x |
|
Silla Sg Co. Ltd
KQ:025870
|
0.474x |
|
Haidemenos S.A.
AT:HAIDE
|
0.043x |
|
Belararox Ltd
AU:BRX
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Adial Pharmaceuticals Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see ADIL market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.28 Million | $-6.49 Million | -1.230x | +27.69% |
| 2024-12-31 | $4.07 Million | $-6.92 Million | -1.702x | -2.08% |
| 2023-12-31 | $4.08 Million | $-6.81 Million | -1.667x | +51.17% |
| 2022-12-31 | $3.28 Million | $-11.19 Million | -3.414x | -0.22% |
| 2021-12-31 | $3.51 Million | $-11.95 Million | -3.407x | -77.89% |
| 2020-12-31 | $3.99 Million | $-7.63 Million | -1.915x | -115.72% |
| 2019-12-31 | $7.14 Million | $-6.34 Million | -0.888x | -57.80% |
| 2018-12-31 | $4.44 Million | $-2.50 Million | -0.563x | -213.40% |
| 2017-12-31 | $-997.55K | $-494.86K | 0.496x | -81.29% |
| 2016-12-31 | $-103.49K | $-274.38K | 2.651x | +192.97% |
| 2015-12-31 | $163.15K | $-465.22K | -2.852x | -- |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more